4-(1H-benzimidazol-4-yl)-1-N-(piperazin-2-ylmethyl)-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide
C19H22N10O4S2 — CID 135311047
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-(1H-benzimidazol-4-yl)-1-N-(piperazin-2-ylmethyl)-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide
4-(1H-benzimidazol-4-yl)-1-N-(piperazin-2-ylmethyl)-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide (PubChem CID 135311047) has the molecular formula C19H22N10O4S2 and a molecular weight of 518.59 g/mol. Its IUPAC name is 4-(1H-benzimidazol-4-yl)-1-N-(piperazin-2-ylmethyl)-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide.
Molecular Properties
| Compound Name | 4-(1H-benzimidazol-4-yl)-1-N-(piperazin-2-ylmethyl)-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide |
|---|---|
| PubChem CID | 135311047 |
| Molecular Formula | C19H22N10O4S2 |
| Molecular Weight | 518.59 g/mol |
| Exact Mass | 518.13 |
| IUPAC Name | 4-(1H-benzimidazol-4-yl)-1-N-(piperazin-2-ylmethyl)-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide |
| SMILES | NS(=O)(=O)c1c(S(=O)(=O)NCC2CNCCN2)ccc(-c2cccc3[nH]cnc23)c1-c1nn[nH]n1 |
| InChI | InChI=1S/C19H22N10O4S2/c20-34(30,31)18-15(35(32,33)25-9-11-8-21-6-7-22-11)5-4-12(16(18)19-26-28-29-27-19)13-2-1-3-14-17(13)24-10-23-14/h1-5,10-11,21-22,25H,6-9H2,(H,23,24)(H2,20,30,31)(H,26,27,28,29) |
| InChIKey | BYOIHNHEFHNPER-UHFFFAOYSA-N |
| XLogP | -1.10 |
| TPSA | 213.53 Ų |
| H-Bond Donors | 6 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 518.59 |
| LogP ≤ 5 | -1.10 |
| H-Bond Donors ≤ 5 | 6 |
| H-Bond Acceptors ≤ 10 | 10 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135311047 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.